Format

Send to

Choose Destination
Expert Opin Drug Saf. 2016 Oct;15(10):1439-48. doi: 10.1080/14740338.2016.1221399. Epub 2016 Aug 19.

Rupatadine: global safety evaluation in allergic rhinitis and urticaria.

Author information

1
a Department of Allergology , Hospital Quirón , Barcelona , Spain.
2
b Upper Airway Research Laboratory, Department of Oto-rhino-laryngology , Ghent University , Ghent , Belgium.
3
c Unitat de Rinologia & Clínica de l'Olfacte, ENT Department , Hospital Clínic i Universitari; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and CIBER de Enfermedades Respiratorias (CIBERES) , Barcelona , Spain.

Abstract

INTRODUCTION:

Rupatadine is a second-generation H1-antihistamine with dual affinity for histamine H1 and PAF receptors. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria.

AREAS COVERED:

A Medline search was conducted to identify preclinical and clinical studies of rupatadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of rupatadine.

EXPERT OPINION:

The review of these data indicates that rupatadine is highly selective for histamine H1-receptors, exhibits additional PAF antagonism in in vitro and in vivo studies, does not cross the blood-brain barrier, and has similar adverse events comparable with other second-generation antihistamines. Rupatadine is a safe and well tolerated drug in patients over 2 years old, with no central nervous system or cardiovascular effects and it can be taken with or without foods.

KEYWORDS:

H1-antihistamine; H1-receptor antagonist; PAF antagonist; Rupatadine; allergic rhinitis; chronic spontaneous urticaria; intermittent; perennial; persistent; pharmacodynamics; pharmacokinetics; safety; seasonal; second-generation antihistamine; therapeutic use; urticaria

PMID:
27500993
DOI:
10.1080/14740338.2016.1221399
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center